Qiong Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiong Wu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jingqiu Zhou
College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China
1 shared publicationJingshu Zhang
College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China
1 shared publicationQiu Jing Zhou
College of Information Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publicationRenyi Zhou
Department of Orthopaedics, The First Hospital of China Medical University, Shenyang, China
1 shared publicationSha Li Meng
College of Information Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publicationTao Wu
College of Information Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publication
Latest Publications
- Open Access
- 14 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1516638
Cellulose nanofiber reinforced curcumin-infused calcium phosphate silicate cement for various bone-tissue engineering application
Introduction: This study utilized a injectable curcumin (Cur)-infused calcium phosphate silicate cement (CPSC) for addressing defects caused by bone cancer, and evaluated its promoting bone regeneration and exerting cytotoxic effects on osteosarcoma cells.Methods: The material’s physicochemical properties, biocompatibility with osteoblasts, and cytotoxicity toward osteosarcoma cells were rigorously analyzed.Results: The findings demonstrate that CPSC-Cur signicantly prolongs the setting time, which can be optimized by adding silanized cellulose nanober (CNF-SH) to achieve a balance between workability and mechanical strength. Biological assessments reveal a pronounced cytotoxic effect on osteosarcoma cells while maintaining minimal toxicity toward pre-osteoblasts, highlighting CPSC-Cur’s potential as a promising material for repairing bone defects following cancer removal.Conclusion: This study lays the groundwork for future investigations into CPSC-Cur’s in vivo efficacy and its role in the clinical treatment of bone cancer.
- 14 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1516638
Open AccessCellulose nanofiber reinforced curcumin-infused calcium phosphate silicate cement for various bone-tissue engineering application
Introduction: This study utilized a injectable curcumin (Cur)-infused calcium phosphate silicate cement (CPSC) for addressing defects caused by bone cancer, and evaluated its promoting bone regeneration and exerting cytotoxic effects on osteosarcoma cells.Methods: The material’s physicochemical properties, biocompatibility with osteoblasts, and cytotoxicity toward osteosarcoma cells were rigorously analyzed.Results: The findings demonstrate that CPSC-Cur signicantly prolongs the setting time, which can be optimized by adding silanized cellulose nanober (CNF-SH) to achieve a balance between workability and mechanical strength. Biological assessments reveal a pronounced cytotoxic effect on osteosarcoma cells while maintaining minimal toxicity toward pre-osteoblasts, highlighting CPSC-Cur’s potential as a promising material for repairing bone defects following cancer removal.Conclusion: This study lays the groundwork for future investigations into CPSC-Cur’s in vivo efficacy and its role in the clinical treatment of bone cancer.
- 16 November 2022
- Published by Springer Nature in Cellulose
- Vol. 30 (2) , 1011-1029
Different cellulose nanofibers impact properties of calcium phosphate silicate cement for bone tissue engineering
- 16 November 2022
- Published by Springer Nature in Cellulose
- Vol. 30 (2) , 1011-1029
Different cellulose nanofibers impact properties of calcium phosphate silicate cement for bone tissue engineering
- Open Access
- 1 August 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (8) , 9057-9068
Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis
Background: Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease, the progression of which current drug therapy cannot reverse. This study analyzed current research hotspots and future research trends in IPF through bibliometric methods, with the aim of providing a reference for new therapeutic strategies. Methods: Publications on IPF obtained from the Web of Science Core Collection database, The Literature Metrology Online Analysis Platform, and CiteSpace were used to analyze publication characteristics. VOSviewer was used to conduct keywords co-occurrence analysis and analyze research hotspots. Results: A total of 7,016 publications related to IPF were identified from 2011 to 2020. The most contributions were from the USA and the five research institutions with the largest number of publications were all from that country. The American Journal of Respiratory and Critical Care Medicine was the most cited journal and had an incontrovertible academic impact with five of the top 10 high-cited references published in this journal. G Raghu was the academic authority in this domain in terms of both the number of publications and the most citations. By analyzing keywords, we identified three IPF research hotspot clusters, which are “clinical research”, “pathogenesis research” and “diagnosis research” respectively. Conclusions: We evaluated all publications concerning IPF research in the past decade through bibliometric analysis. The current research hotspot in this field is drug therapy for the condition using nintedanib and pirfenidone. Future research will focus on conducting multi-center randomized controlled trials to explore and evaluate new therapeutic drugs for IPF. It is hoped that this study can provide information and data support for further research and the development of new therapeutic drugs.
- 1 August 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (8) , 9057-9068
Open AccessGlobal research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis
Background: Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease, the progression of which current drug therapy cannot reverse. This study analyzed current research hotspots and future research trends in IPF through bibliometric methods, with the aim of providing a reference for new therapeutic strategies. Methods: Publications on IPF obtained from the Web of Science Core Collection database, The Literature Metrology Online Analysis Platform, and CiteSpace were used to analyze publication characteristics. VOSviewer was used to conduct keywords co-occurrence analysis and analyze research hotspots. Results: A total of 7,016 publications related to IPF were identified from 2011 to 2020. The most contributions were from the USA and the five research institutions with the largest number of publications were all from that country. The American Journal of Respiratory and Critical Care Medicine was the most cited journal and had an incontrovertible academic impact with five of the top 10 high-cited references published in this journal. G Raghu was the academic authority in this domain in terms of both the number of publications and the most citations. By analyzing keywords, we identified three IPF research hotspot clusters, which are “clinical research”, “pathogenesis research” and “diagnosis research” respectively. Conclusions: We evaluated all publications concerning IPF research in the past decade through bibliometric analysis. The current research hotspot in this field is drug therapy for the condition using nintedanib and pirfenidone. Future research will focus on conducting multi-center randomized controlled trials to explore and evaluate new therapeutic drugs for IPF. It is hoped that this study can provide information and data support for further research and the development of new therapeutic drugs.